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Genomics or, in other words, genome-based biology
offers an entirely new prospective on strategies applicable
to the study of distinct physio-pathological conditions
through a "discovery-driven" approach that may comple-
ment traditional "hypothesis-driven" scientific thinking
[1-3]. Indeed, analysis of genomic variation at the DNA
level and functional genomics that addresses transcrip-
tional variations of biological material have been exten-
sively used by bio-scientists to study distinct pathological
conditions and this trend has spread, more recently to
applications in basic and clinical immunology [4-9]. This
shift in paradigm in the study of biology and, for the pur-
pose of this Commentary, in immunology may very well
be suitable for the understanding of immune regulation
in sickness and in health which represents a particularly
complicated biological matter due do the extreme versatil-
ity of the immune system in adaptation to environmental
changes. The study of immune regulation in response to
pathogen invasion, presence of malignant or allogeneic
tissue and, in some cases, toward normal autologous tis-
sue may require global approaches that could study in
parallel the behavior of whole-systems. In fact, the study
of single immunological parameters has, so far, failed to
unlock several questions related to the immune-system
complexity. This may be particularly true for tumor
immunology that is a compound field in which the
dynamic heterogeneity of cancer cells [10] supplements
the complexity of polymorphic variation and epigenetic
adaptation characteristic of human immunology [11]. In
fact, new tools have been developed that allow a global
vision of genetic processes in parallel at various levels that
encompass genetic variation (single nucleotide polymor-
phism analysis), epigenetic changes (i.e. methylation-
detection arrays or comparative genomic hybridization
that can detect gene methylation or deletion / amplifica-
tion respectively) and global transcription analysis (i.e.
cDNA- or oligonucleotide-based microarrays like the lym-
pho-chip or the peptide-MHC microarrays) that com-
bined with bio-informatics tools provide a new approach
to the description of complex immunological phenomena
[3,9,11-14].
It is likely that, database mining will supplement classical
experimentally-driven scientific thinking with a more
interactive "in-silicon" processing of information inte-
grated by software programs capable to link information
accessible from the literature with extensive data bases
from different laboratories for the simple purpose of
increasing the data pool from which generate new
hypotheses. Thus, we propose the new word: "immunog-
enomics" to describe the switch from the paradigm of
solely hypothesis-driven immunological research to a
more interactive and flexible relationship between classi-
cal research and a discovery-driven approach. It also
appears to us that immunogenomics may particularly suit
clinical immunology for the simple reason that genetic
variation of patients and their diseases is not as controlla-
ble in humans as it is in inbred animal models [15]. Thus,
since simplification is not an option when studying
human biology, approaches that could collect informa-
tion about such variation whether relevant or irrelevant to
a physio-pathological condition may offer the opportu-
nity to sort causative relationships from simple associa-
tions among molecular pathways. We want to emphasize,
however, that immunogenomics is not in competition
with traditional hypothesis-driven science but rather the
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"fishing expedition" of large data set formation should
complement traditional approaches by identifying new or
validate known concepts that best fit the reality of human
diseases.
At least four major aspects of immunogenomics could be
identified. Immunogenomics covers:
1. The convergence of distinct elements of the immune
system into a network of information regarding the local-
ization, gene structure and expression profile of various
players of the innate and/or acquired immune response;
2. Genetic regulation of physiological immune functions
by inherited or epigenetic processes such as immunoglob-
ulin or T cell receptor gene rearrangement, somatic hyper-
mutation, immune selection in primary and peripheral
immune tissues, antigen processing and presentation by
major histocompatibility molecules, cytotoxic interac-
tions, etc.
3. Genetic changes in immune function in pathological
conditions such as onco-hematological diseases, allergy,
immune deficiencies, infections, chronic inflammation,
autoimmunity and cancer.
4. Suggest personalized approaches to immune therapy by
predicting successful treatment or deleterious side effects
and, therefore, helping in the selection of treatments
appropriate for individual patients. This new era will start
when such alterations could be easily collected during
clinical trials through inexpensive high-throughput meth-
ods for detection of genomic variation or for expression
profiling that could be applied to large patient popula-
tions [3,11,14]. With this strategy it will then be possible
to immune phenotype individuals according to their
genetic make-up and the epigenetic adaptations of their
immune system. Hopefully, the kinetics of individual
immune responses, the network in which they will oper-
ate and their vulnerability in sickness or in health may be
predicted for each individual [16].
The global– immunogenomics approach stands on three
foundations; (i) the revolutionary expansion of genome
knowledge that is now available in giant computer data-
banks [17,18]; (ii) robust nanotechnology such as micro-
array chips and similar tools that allow real-time
measurement of gene variants and gene expression and
(iii) availability of improving software principles in
immune bioinformatics that could generate data-mining
tools for an efficient interpretation of otherwise unman-
ageable biological information.
This interdisciplinary thinking process asks for active
cooperation among related scientific fields. The impor-
tance of scientific workshops and conferences inclusive of
convergent topics and expertise may significantly increase
the potential for a multi-directional transfer of knowl-
edge. Good examples are the Workshop on Cancer Bio-
metrics for Immunological Monitoring recently held at
the National Institutes of Health, Bethesda, MD [19] and
the First Conference on Basic and Clinical Immunoge-
nomics soon to be held in Budapest this October http://
www.diamond-congress.hu/bci2004/. In fact, although
the potentials of high-throughput analyses applied to
human biology are conceptually obvious, several obsta-
cles remain not only of technological nature but also in
the design of clinical trials and education of clinical scien-
tists about the opportunities available for the selection,
treatment and monitoring of patients entered in clinical
trials. Comprehensive reviews on this subject, contrary to
those detailing technical information, are scant and com-
munication between bench and clinical scientists remain
below a threshold likely to produce efficient therapy
development and ultimately benefit patients. Although,
tools are available nowadays to study biological processes
in their globality [3], clinical samples of appropriate rele-
vance and quality are not easily accessible. In spite of the
fact that individual genetic predisposition to disease and
response to treatment [14,11] could be studied in combi-
nation with that of epigenetic changes during life and dis-
ease progression [3] and that of real-time adaptation in
the transcriptional profile of biological samples in rele-
vant conditions [3] very little has been done to prospec-
tively collect clinical material. Thus, availability of
relevant samples to study remains the central problem. In
particular, functional genomic studies rely on the fine
measurement of messenger RNA levels highly susceptible
to metabolism and degradation. Thus, the design of clini-
cal studies should incorporate strategies that may lead to
the understanding of the biology of tissues or pathogens
targeted by immune effectors, their relationship with the
host and their response/adaptation to therapy while test-
ing at the same time the clinical efficacy of a given treat-
ment [15]. In fact the understanding of disease is a
requirement for the design of rational therapies. High-
throughput technologies [3] will allow, when applied to
relevant samples, the efficient screening in humans of the-
oretical models generated from animal experimentation,
in vitro studies or speculation and, in turn, the discovery
of new patterns through the direct observation of human
pathology but this will only occur through the integrated
efforts of multiple basic and clinical research disciplines.
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